News | Peripheral Artery Disease (PAD) | March 09, 2017

Medtronic Launches European Below-the-Knee IN.PACT Clinical Study

First procedure in prospective, randomized, multi-center study of drug-coated balloon technology in treatment for PAD performed at Maria Cecilia Hospital in Italy

Medtronic, IN.PACT Admiral DCB, drug-coated balloon, below-the-knee, European BTK IN.PACT clinical study, peripheral artery disease, PAD, launch

March 9, 2017 — Medtronic plc announced the launch of the IN.PACT BTK study to evaluate the effectiveness of a drug-coated balloon (DCB) in patients with below-the-knee (BTK) peripheral arterial disease (PAD). This study will evaluate the IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter. This is an investigational device, which uses Medtronic’s IN.PACT Admiral drug coating technology. 

Antonio Micari, M.D., of Maria Cecilia Hospital in Cotignola, Italy, performed the first procedure on a patient with critical limb ischemia (CLI). Micari reports the first patient is doing well post-treatment.

“The first patient enrollment in the IN.PACT BTK study marks a landmark milestone in identifying a treatment option for below-the-knee PAD,” said Micari. “Given the chronic nature and co-morbidities of this disease, there is a critical need for treatment options that are safe and durable. I look forward to continuing patient enrollment to evaluate the use of this DCB in treating this challenging disease state.”

CLI with PAD below-the-knee is associated with risk of non-healing wound ulcers and amputation. This complex disease is one of the most significant clinical challenges for physicians in the clinical vascular community.

“Patency rates after conventional balloon angioplasty can be challenging in BTK disease, and we believe that a sustained patency could improve healing and reduce the need of target lesions revascularization (TLR) and major amputation,” said Francesco Liistro, M.D., chief of cardiovascular intervention at San Donato Hospital, Arezzo, Italy. “Multiple studies have evaluated DCBs in the superficial femoral arteries (SFA), but the need for clinically supported treatment options for below-the-knee PAD still remains. We look forward to participating in this significant trial to evaluate the IN.PACT 0.014 DCB in a complex CLI patient population, particularly given the strong evidence for use of IN.PACT Admiral in the SFA.” 

The IN.PACT BTK study is a prospective, randomized, multi-center study that will enroll approximately 60 patients at four sites in Europe. The study’s primary endpoint is late lumen loss at nine months, an important angiographic measure of drug effectiveness, in patients who received treatment with the IN.PACT 0.014 DCB compared to standard PTA. The study also includes a wound care protocol, which provides additional safety controls and ensures patients will routinely undergo routine and standard monitoring by qualified wound care professionals.

Medtronic partnered closely with the clinical community to further understand the complexity of this disease state and build on the emerging body of scientific knowledge regarding use of DCBs below-the-knee. This includes findings from Medtronic’s IN.PACT DEEP trial, which used an earlier balloon technology. Additionally, at the 2016 Transcatheter Cardiovascular Therapeutics meeting (TCT 2016), Juan F. Granada, M.D., presented pre-clinical data on wound healing in a porcine model. The findings indicated that the use of the IN.PACT Admiral drug-coated balloon in the SFA territory does not delay wound healing despite measureable concentrations of paclitaxel in the adjacent cutaneous tissue.

The IN.PACT 0.014 DCB is an investigational device being evaluated in Europe and does not have an approved Investigational Device Exemption in the United States.

For more information: www.medtronic.com

Related Content

Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter| November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter| March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter| January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter| October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init